Hepatitis C treatment hesitancy among people with heroin dependence in Australia. A prospective cohort study

Tremonti, Chris; Teesson, Maree; Marel, Christina; Mills, Katherine L.; Haber, Paul S.

doi:10.5694/mja2.52013

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To achieve global HCV elimination by 2030, people who use drugs (PWUD) need to be a priority for engagement and treatment. However, some healthcare professionals (HCPs) treating hepatitis C remain concerned about the potential for drug–drug interactions (DDIs) between opioids, such as fentanyl and DAAs [ 8 ]. The Liverpool HEP Drug Interaction Tracker, which relies upon publicly available pharmacokinetic (PK) parameters and prescribing information [ 9 ], lists elbasvir/grazoprevir (EBR/GZR) and G/P as having a “potential interaction” when used concomitantly with prescribed fentanyl, oxycodone and hydrocodone, due to weak CYP3A inhibition by the protease inhibitors grazoprevir and glecaprevir, respectively.…”

Section: Introductionmentioning

confidence: 99%

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

Martinez,

Khan,

Dylla

et al. 2023

Harm Reduct J

View full text Add to dashboard Cite

Introduction Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs. Methods AEs reported (July 28, 2017–December 31, 2021) with the administration of the DAAs glecaprevir/pibrentasvir, sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, sofosbuvir/velpatasvir/voxilaprevir, and elbasvir/grazoprevir as suspect products were downloaded from the US Food and Drug Administration AE Reporting System Public Dashboard. The number of AE reports containing opioids (fentanyl, hydrocodone, oxycodone) as co-suspect products/concomitant products were counted and summarized by severity, reporting country and whether an outcome of death was reported. Overdose AEs were counted irrespective of opioid use, and changes over time were assessed. Results In total, 40 AEs were reported for DAAs and concomitant fentanyl use, 25 (62.5%) were in the USA, 35 (87.5%) were considered serious, and 14 (35.0%) resulted in death; and 626 were reported with concomitant oxycodone/hydrocodone use, 596 (95.2%) were in the USA, 296 (47.3%) were considered serious, and 28 (4.5%) resulted in death. There were 196 overdose AEs (32 [16%] deaths) declining from 2018 (N = 56) to 2021 (N = 29). Conclusions Treating people with hepatitis C virus (HCV) infection who use drugs is key to achieving HCV elimination. Low numbers of DAA AE reports with opioids may provide reassurance to prioritize HCV treatment in this population. These data contribute to evidence supporting the continued scale-up of DAA treatment among people who use drugs to achieve HCV elimination goals.

show abstract

Section: Introductionmentioning

confidence: 99%